Home›People›Heiner Dreismann
Heiner Dreismann

Heiner Dreismann

Director at Inflammatix

DirectorRoles at 2 startups
Updated Nov 19, 2026·Latest SEC filing Nov 19, 2026·Suggest an edit

About Heiner Dreismann

Heiner Dreismann is a director at Inflammatix. He joined its board in July 2023. Inflammatix develops rapid tests that read immune responses to help doctors diagnose acute infections and sepsis. He has more than 35 years of life sciences and health care experience. His career included early use of a common laboratory method called polymerase chain reaction, or PCR.

He earned graduate degrees in biology and microbiology at Westfaelische Wilhelms University. After a postdoctoral fellowship near Paris, he joined Roehm and Haas. He joined F. Hoffmann La Roche in 1985 and later led its European PCR business and strategic planning for PCR diagnostics. From 2000 through 2006, he was president and CEO of Roche Molecular Systems. He was CEO of Vectrant Technologies from 2006 through 2009 and became interim CEO of GeneNews in 2008. Singulex appointed him to its board in 2007. He later served there as lead independent director. In 2012, he also served on the Myriad Genetics, Med BioGene and GeneNews boards.

Experience

This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Heiner Dreismann in the role, so the role may have started earlier or lasted longer.

Inflammatix, Inc. Current
Director
2023 – Present · Sunnyvale, CA
Inflammatix helps emergency teams identify infection type and illness severity from the body's immune response.
Ixcela, Inc.
Director
2017 · Beverly, MA
Virtual dietitian care and gut health testing for patients with a range of health concerns.
Vectrant Technologies, Inc.
Chief Executive Officer
2006 – 2009
GeneNews Limited
Interim Chief Executive Officer (From 2008)
Director
From 2008
Roche Molecular Systems
President and CEO
2000 – 2006
F. Hoffmann La Roche AG
From 1985
Roehm and Haas
French Center for Nuclear Research
post-doctoral fellowship
Singulex Inc.
Lead Independent Director
Myriad Genetics, Inc.
Director
Med BioGene Inc.
Director

Key Colleagues at Startups

The people Heiner Dreismann works with at each company, as listed on that company's latest Form D.

Inflammatix, Inc. · Form D, Nov 19, 2026
Timothy Sweeney
Timothy Sweeney
Co-Founder and CEO, director
FK
Florian Kainzinger
Founder, Think.Health Ventures and director
IC
Ingo Chakravarty
Operating Partner at Northpond Ventures and director
Steven Tablak
Steven Tablak
Former Chairman and CEO, GeneWeave
JR
Jonathan Romanowsky
Co-Founder and director
David Persing
David Persing
EVP/Chief Medical Officer, Cepheid and director
Ixcela, Inc. · Form D/A, Nov 29, 2017
RC
EA
Erika Angle
President and director
NS
Nick Soloway
Director
WM
Wayne Matson
Director
CA
Colin Angle
Executive officer and director

Sources

  1. SECInflammatix, Inc. Form D, filed Nov 19, 2026
  2. SECIxcela, Inc. Form D/A, filed Nov 29, 2017
  3. P2PR Newswire — Inflammatix Appoints Heiner Dreismann as New Board Member
  4. P3Inflammatix — Home
  5. P5Singulex Inc. 2012 filing
  6. S5Interpace filing result naming Ixcela